MORGANTOWN, W.V., April 8, 2014 (GLOBE NEWSWIRE) -- Protea Biosciences Group, Inc. (OTCBB:PRGB) ("Protea"), announced today that Greg Kilby, Ph.D. has joined the Company as its Chief Bioanalytics Officer (CBO) and Director of Biomolecular Information Services. Prior to joining Protea Dr. Kilby held the position of Director, North America Life Sciences Mass Spectrometry Application and Demonstration Laboratories for Thermo Fisher Scientific (NYSE:TMO) and previously held positions at Agilent Technologies, Inc. and Pfizer, Inc.
"We are delighted to have Greg join our team here at Protea," commented Steve Turner, Protea's CEO. Turner added, "With the demand we are experiencing for our biomolecular information services, we are expanding our capabilities. Dr. Kilby's extensive knowledge and experience will help assure we achieve our growth objectives for our molecular information business."
Under Dr. Kilby's leadership, Protea has acquired and installed a Bruker UltrafleXtreme MALDI TOF/TOF mass spectrometer to expand the Company's capabilities in mass spectrometry imaging for large molecules, to complement its existing mass spectrometry imaging capabilities via its proprietary LAESI® technology. In addition, Protea has hired Erin Seeley, Ph.D., Senior Lead Scientist, Mass Spectrometry Imaging. Prior to joining Protea, Dr. Seeley was Associate Director of the Tissue Imaging Core Laboratory at Vanderbilt University.
"Mass spectrometry imaging has significant potential to impact many fields of scientific endeavor, ranging from agriculture to clinical," said Dr. Kilby. "It is exciting to join an organization that is rapidly establishing commercial leadership in this emerging field and to explore and commercialize novel ways of approaching very challenging science and biology by blending established bioanalytical technologies with mass spectrometry imaging. I am pleased to work with this outstanding team, and I look forward to contributing to the future growth and success of Protea Biosciences."
Protea Biosciences Group, Inc.
Protea is a commercial stage molecular information company, leading in the field of mass spectrometry molecular imaging - the identification and localization of the molecular products of living cells, that is foundational science for all pharmaceutical, medical, and life science research.
Forward-Looking Statements
This press release may contain certain statements relating to future results which are forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further information concerning the Company and its business, including factors that potentially could materially affect the Company's financial results, are contained in the Company's filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Protea and LAESI are registered trademarks of Protea Biosciences Group, Inc.